| 0.8369 0.07 (9.16%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.61 | 1-year : | 2.09 |
| Resists | First : | 1.38 | Second : | 1.78 |
| Pivot price | 0.85  |
|||
| Supports | First : | 0.72 | Second : | 0.6 |
| MAs | MA(5) : | 0.8 |
MA(20) : | 0.95 |
| MA(100) : | 1.1 |
MA(250) : | 1.82 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 13.2 |
D(3) : | 11.5 |
| RSI | RSI(14): 42.7 |
|||
| 52-week | High : | 5.48 | Low : | 0.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ISPC ] has closed above bottom band by 44.3%. Bollinger Bands are 46.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.91 - 0.91 | 0.91 - 0.92 |
| Low: | 0.75 - 0.76 | 0.76 - 0.76 |
| Close: | 0.83 - 0.84 | 0.84 - 0.84 |
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Sun, 14 Sep 2025
iSpecimen Faces Potential Stock Market Stir with Recent Regulatory Amendments - StocksToTrade
Sat, 13 Sep 2025
iSpecimen Stock Soars Amid New Securities Filing News - StocksToTrade
Thu, 04 Sep 2025
iSpecimen Approached by Crypto Currency Companies for $200 Million Treasury Discussions - Newsfile
Thu, 21 Aug 2025
iSpecimen completes first phase of digital transformation program - Investing.com
Thu, 21 Aug 2025
iSpecimen Announces Completion of Milestone 1 in Digital Transformation Journey with Salestack Platform - Newsfile
Thu, 21 Aug 2025
iSpecimen’s Real Value: A Functioning Life Sciences Business Backed by a Planned $200M Digital Treasury (NASDAQ: ISPC) - Barchart.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 8 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 1.2 (%) |
| Shares Short | 294 (K) |
| Shares Short P.Month | 385 (K) |
| EPS | -8.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | -172.6 % |
| Operating Margin | -255.5 % |
| Return on Assets (ttm) | -76.7 % |
| Return on Equity (ttm) | -303.8 % |
| Qtrly Rev. Growth | -75.1 % |
| Gross Profit (p.s.) | 0.23 |
| Sales Per Share | 0.71 |
| EBITDA (p.s.) | -1.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | 3.34 |
| Price to Sales | 1.16 |
| Price to Cash Flow | -1.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|